If bacteria aren’t the whole story of the tumor microenvironment, what crucial signals are being missed from fungi that quietly occupy the same space yet account for only a sliver of the sequencing reads but a disproportionate share of immune cues and clinical outcomes? That challenge has gained
Julia Lainster sits down with Ivan Kairatov, a seasoned biopharma leader with deep experience in oncology R&D, to unpack the latest data from OptiTROP-Lung05 and what it could mean for first-line NSCLC. They explore how a TROP2-directed antibody-drug conjugate combined with an immune checkpoint
In a world where patients often wait nearly a year for life-saving drugs to gain approval, a groundbreaking initiative by the FDA is slashing that timeline to mere weeks, promising a dramatic shift in biopharma. The Commissioner’s National Priority Voucher (CNPV) pilot program is not just speeding
Ivan Kairatov is a biopharma expert with a track record bridging preclinical discovery and translational development across oncology subtypes. He has worked at the interface of receptor biology, pharmacology, and clinical trial design, and he brings a pragmatic lens to drug repurposing. In this
Could a single seed pull double duty against inflammation, oxidative stress, microbes, and metabolic drift without the side-effect ledger that shadows many prescriptions, and could it do so in a way that complements rather than competes with standard care? That is the provocation driving a surge of
In a world where a stroke strikes someone every 40 seconds, the fear of a second, potentially fatal event looms large for millions of survivors, creating an urgent need for better solutions. Picture a patient, just recovered from an initial stroke, grappling with the uncertainty of whether their
